Global Access Programs: A Collaborative Approach for Effective Implementation and Management.

Area of Science:

• Pharmaceutical Medicine
• Regulatory Science
• Health Policy

Background:

• Global Access Programs (GAPs) facilitate patient access to investigational medicines when no other options exist.
• Pharmaceutical companies face challenges in establishing GAPs due to competing priorities like clinical trials and marketing authorization.
• GAP implementation requires distinct expertise, infrastructure, and navigation of complex, variable regulatory landscapes.

Purpose of the Study:

• To explore triggers for early access requests and advocate for global strategies for GAPs.
• To provide a comprehensive overview of GAP processes, from setup to closure.
• To discuss critical considerations influencing GAP design and execution.

Main Methods:

• Literature review and analysis of existing frameworks for early access programs.
• Examination of regulatory requirements and variations across different countries.
• Case study considerations for GAP scope, including demand, feasibility, and company strategy.

Main Results:

• Requests for early access often arise during critical company milestones, demanding specialized management.
• Successful GAPs necessitate a global strategy, addressing regulatory, logistical, and operational complexities.
• Key factors influencing GAP scope include patient demand, regulatory approval, product licensing, pricing, and supply chain management.

Conclusions:

• Well-managed GAPs are crucial for providing ethical and compliant access to novel treatments for unmet medical needs.
• Strategic planning and efficient management are essential throughout the lifecycle of a Global Access Program.
• Companies must assess internal capabilities and consider external partnerships for effective GAP execution.